Request Demo
Microsoft and NVIDIA expand collaboration in healthcare innovation
19 Mar 2024
The partnership will aid in faster drug discovery. Credit: Elnur / Shutterstock.com.
Microsoft has announced plans to broaden its partnership with NVIDIA to leverage generative AI, cloud technology and accelerated computing to enhance healthcare and life sciences innovation.
The initiative will offer healthcare providers, pharmaceutical companies and medical devNVIDIAnufacturers opportunities to execute swift innovations in clinical research, drug discovery and care delivery.
The key features of the partnership include accelerated drug discovery with BioNeMo on NVIDIA’s DGX Cloud, hosted on Azure.
This approach will aid in expediting clinical research and drug discovery and boost accNVIDIA precision therapies.
See Also:
Biotheus and Hansoh Pharmaceutical expand ADC collaboration
Biotheus PrevHansoh Pharmaceuticalbel for ADCiatric streptococcal pneumonia
The collaboration will bolster clinical research and care delivery using imaging-based AI diagnostic technology through Azure, NVIDIA MONAI and the Nuance Precision Imaging Network.
Pfizeral Prevenaro expedite genomics analypediatric streptococcal pneumoniaon Azure, powered by NVIDIA Parabricks.
Microsoft Health & Life Sciences corporate vice-president Peter Durlach stated: “Microsoft is building on its longstanding collaboration with NVIDIA to empower the healthcare and life sciences industry with the power of Azure and generative AI, helping unlock new horizons for clinical research, drug discovery and patient care worldwide.
“Through this collaboration, we aim to help the industry unlock breakthroughs in healthcare, making care more precise, accessible and effective to deliver a meaningful difference in the lives of patients globally.”
Cognizant is also advancing the application of generative AI technology with the NVIDIA BioNeMo platform to address drug discovery challenges in life sciences.
By utilising generative AI technologies, clinical researchers, can quickly navigate vast datasets, predict drug compound interactions more accurately, and set out new drug development pathways.
Cognizant, with its deep expertise in life sciences and AI, aims to provide clients with access to BioNeMo’s pre-trained generative AI models, frameworks and application programming interfaces for rapid model training and customisation using proprietary data.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.